Symbiotec Pharmalab IPO GMP, Date, Price Band & Review

Symbiotec Pharmalab IPO Details

Symbiotec Pharmalab IPO is a book-built mainboard issue of ₹1,757 crore, comprising a fresh issue of ₹150 crore and an offer for sale (OFS) of up to ₹1,607 crore by existing shareholders. The final issue is smaller than the ₹2,180 crore proposal outlined in the earlier draft papers because the OFS component was reduced, while the fresh issue size was retained at ₹150 crore. The equity shares have a face value of ₹2 each and are proposed to be listed on the BSE and NSE.

The price band is fixed at ₹938–₹988 per share, and the market lot is 15 equity shares. The minimum investment required by an individual investor is ₹14,820 for one lot of 15 shares at the upper price band. The IPO will open for subscription from August 24 to August 27, 2026, with a tentative listing date of September 1, 2026. The book-running lead managers are JM Financial Limited, Avendus Capital Private Limited, Motilal Oswal Investment Advisors Limited and Nomura Financial Advisory and Securities (India) Private Limited, while MUFG Intime India Private Limited is the registrar to the issue.

Symbiotec Pharmalab IPO Date & Timeline

The Symbiotec Pharmalab IPO is scheduled to open for subscription on August 24, 2026 and close on August 27, 2026. The anchor investor allocation is scheduled for August 21, 2026. Once the subscription window closes, the basis of allotment is expected to be finalised on August 28, 2026. Refunds are expected to be initiated and shares credited to successful investors’ demat accounts on August 31, 2026. Finally, shares of Symbiotec Pharmalab Limited are tentatively scheduled to list on the BSE and NSE on September 1, 2026.

Symbiotec Pharmalab IPO GMP

“Grey Market Premium” or GMP is defined as the rate at which the IPO's shares are traded in the market before they are officially listed on the stock exchange.

The Symbiotec Pharmalab IPO GMP is currently trading at ₹185, reflecting the sentiment of unofficial investors before the official listing. This premium suggests a potential listing price of 1173, which is 18.72% above the issue price. While the Grey Market Premium is a key indicator of demand and investor appetite, it is important to remember that GMP is highly volatile and should not be the sole factor in your investment decisions.

Company Background

Symbiotec Pharmalab Limited is an Indore, Madhya Pradesh-based pharmaceutical and biotechnology company focused on active pharmaceutical ingredients (APIs), contract development and manufacturing organisation (CDMO) services, and complex injectable products. The company operates through a vertically integrated platform spanning organic chemistry, biotechnology and pharmaceutical manufacturing.

The company is known for manufacturing corticosteroid and steroidal-hormone APIs. Its operations are supported by research and development, fermentation, organic-synthesis and dosage-form capabilities, enabling it to participate across multiple stages of the pharmaceutical value chain.

Operations and Product Range

Symbiotec Pharmalab serves pharmaceutical customers through APIs, CDMO solutions and complex injectables. Its business portfolio includes:

• • Corticosteroid APIs: Active pharmaceutical ingredients used in anti-inflammatory and related therapeutic applications
• • Steroidal-hormone APIs: Products used in hormonal and reproductive-health therapies
• • CDMO services: Development and manufacturing support for pharmaceutical customers
• • Biotechnology products: Fermentation and recombinant-protein capabilities, including work associated with GLP-1 and insulin
• • Complex injectables: Higher-value pharmaceutical dosage-form development and manufacturing

The company’s model combines manufacturing, R&D, quality systems and regulatory-compliance capabilities to serve domestic and international pharmaceutical customers.

Facilities and Capacity

Symbiotec operates regulated pharmaceutical manufacturing facilities in Madhya Pradesh, supported by R&D and quality-control infrastructure. Its capacity is shaped by regulatory approvals, fermentation and synthesis capabilities, product registrations, technical talent, capacity utilisation and the ability to retain global pharmaceutical customers.

As a regulated API and CDMO business, the company’s ability to commission new capacity, maintain compliance during inspections and secure product approvals is central to converting manufacturing capability into commercial revenue.

Brands and Market Presence

Symbiotec primarily operates as a B2B pharmaceutical manufacturer and CDMO rather than as a consumer-facing medicines brand. Its market presence rests on product quality, regulatory credentials, technical expertise, customer relationships and its position in corticosteroid and steroidal-hormone APIs.

The company serves pharmaceutical customers in India and international markets. Its participation in higher-value APIs, CDMO services and complex injectables may support diversification beyond commodity API categories, although this depends on regulatory execution and commercial scale-up.

Revenue Streams and Business Model

Symbiotec earns revenue primarily from the sale of APIs, contract development and manufacturing services, and pharmaceutical and biotechnology products. Its integrated model allows it to source and process inputs, manufacture regulated products and supply pharmaceutical customers under prescribed quality and regulatory standards.

Revenue growth depends on customer orders, product mix, capacity utilisation, regulatory approvals, international demand, raw-material availability, pricing and sustained compliance with manufacturing standards. The business also requires ongoing investment in R&D, plant validation, quality systems and working capital.

Financial Performance

Symbiotec Pharmalab Limited reported revenue of ₹869.15 crore in FY26, compared with ₹751.55 crore in FY25, ₹716.25 crore in FY24 and ₹566.51 crore in FY23. Revenue increased by approximately 15.6% in FY26, following growth of around 4.9% in FY25.

Profit after tax (PAT) rose to ₹109.90 crore in FY26 from ₹96.79 crore in FY25. PAT was ₹100.06 crore in FY24 and ₹23.49 crore in FY23.

The balance sheet strengthened in FY26: net worth increased to ₹1,158.64 crore from ₹821.15 crore in FY25, while total borrowings declined to ₹387.91 crore from ₹540.92 crore. Total assets rose to ₹1,780.79 crore, and reserves increased to ₹1,145.95 crore.

Management and Shareholding

Symbiotec Pharmalab is promoted by Mr. Anil Satwani, Mr. Kashish Satwani, Mr. Sushil Satwani and Satwani Holdings LLP. The IPO comprises a ₹150 crore fresh issue and an OFS of up to ₹1,607 crore. The OFS includes shares offered by existing shareholders, including promoter-linked entities and financial investors such as Rosewood Investments and India Business Excellence Fund III.

The fresh issue will add new capital to the company, while the OFS will transfer existing shares from selling shareholders to public investors. The proceeds from the OFS will go to the respective selling shareholders and will not be received by the company.

Board and Key Management

The board is led by Mr. Anil Satwani, Chairman and Managing Director. IPO-related disclosures identify Mr. Rohit Mantri and Mr. Hariharnath Buggana among the non-executive or nominee directors. The professional management team includes Mr. Salil Jain, Company Secretary, and Mr. Giraj Daga, Chief Financial Officer.

The leadership team oversees API and CDMO operations, research and development, manufacturing quality, regulatory compliance, international customer relationships and expansion into specialised pharmaceutical products.